The Spanish Registry of Clinical Studies (REec), managed by the Spanish Agency of Medicines and Medical Devices (AEMPS), has reached a significant milestone by publishing its 10,000th clinical trial.

The MHRA’s 2024/25 business plan offers exciting opportunities for pharmaceutical companies looking to bring innovative medicines and devices to market. Key priorities include maintaining public trust, improving regulatory excellence through strategic partnerships, and enhancing service delivery with new IT systems like SafetyConnect and RegulatoryConnect. The plan also supports UK life sciences growth, pandemic preparedness and sustainability efforts in healthcare product regulation.

We are now less than three months away from the introduction of the Joint Clinical Assessment (JCA) for ATMPs and oncology products – representing a significant landscape shift for the European Pharmaceutical sector.  

Faced with the many new treatments in development for Heart Failure and the prospect of assessing value relative to effective and largely genericised standard of care – should we start to think differently about how we classify and measure effectiveness in heart failure?

Personalised medicine is altering the healthcare landscape by providing individualised therapeutic methods based on unique patient characteristics. This shift presents a complex array of opportunities and challenges for manufacturers developing precision therapies, particularly in navigating the evolving health technology assessment (HTA) processes.

Australia publishes recommendations for a new HTA roadmap to improve market access and faster patient uptake of new medicines by the end of 2024

There is consensus among patients, clinicians, industry and the government that the time to access new health technologies in Australia is too long and that HTA methods must be sustainable for future innovations in medical technology.

The Innovative Medicines Fund was launched in June 2022 to ensure patient access to promising non-cancer medicines when further data are necessary to resolve outstanding uncertainty. Until recently, only four products had received interim funding through the IMF and there were no formal NICE recommendations for managed access under this agreement.
On 24th July 2024, NICE published the final draft guidance for Hemgenix (etranacogene dezaparvovec), which was ‘recommended with managed access as an option for treating moderately severe or severe haemophilia B (congenital factor IX [FIX] deficiency) in adults without anti‑FIX antibodies’.

On 3rd June 2024, a new collaboration, Joint Nordic HTA Bodies (JNHB), was announced, aiming to streamline health technology assessments (HTAs) in the Nordics through joint HTA assessment of medicinal products.

This second article on the current and fascinating developments in artificial intelligence (AI) will dive deeper into the evaluation of synthetic control arms (SCAs). If you are new to synthetic data or missed the first article, make sure to catch up here. As a reminder, synthetic data are created by generative AI models trained to learn the patterns and statistical properties of a sample real-world data set.

Spain has become a global leader in clinical trials due to the strength of its healthcare system and professionals, pioneering regulatory work, public-private collaboration, and the generosity of patients. Farmaindustria highlights these factors, especially on International Clinical Trials Day, while also pointing out new challenges to maintain this leadership.

In recent weeks, Germany's Federal Council (Bundesrat) voiced their disapproval of the proposal for confidential discounting following a read-out of the Medical Research Act (MFG), echoing the same recommendation to reject the proposal reached by the Federal Health Committee.

Earlier this year the UK Department of Health and Social Care (DHSC) concluded a consultation on its revised proposals to update the 5-year Statutory Scheme for cost-containment of NHS spending on branded medicines, with additional updates phased in throughout the year, here we take a look at the most recent changes

The Italian Medicines Agency (AIFA) has restructured its evaluation process by merging the Technical-Scientific Advisory Commission (CTS) and the Pricing and Reimbursement Committee (CPR) into a single entity, known as the Commissione Scientifica ed Economica del farmaco (CSE).

This new guideline provides recommendations for setting criteria and procedures that govern drug pricing decisions and market entry or withdrawal of new pharmaceuticals, offering a framework for their subsequent re-evaluation.

At Decisive Consulting, we are exploring the complex considerations surrounding access to innovative gene therapies for sickle cell disease, a rare disease with high unmet need.

In celebration of International Women’s Day 2024, Decisive Consulting are proud to explore and provide insight for our community on the importance of advocating for inclusion in healthcare and academia.

Since the Innovative Medicines Fund (IMF) launched in June 2022, NICE has yet to make a recommendation for managed access under this agreement. However, four drugs have received interim funding through the IMF. To learn a bit more about this managed access agreement, Decisive Consulting conducted a review of publicly available sources. Megan Watts sought to understand the decision-making criteria for the IMF and gather learnings from the four analogues with interim funding. For companies with medicines that may be candidates for IMF, keeping informed with the latest IMF updates and proactively engaging with NICE and NHS England will be key.

As we look to commemorate World Rare Disease Day on 29th February, we are reminded of the profound challenges faced by individuals and families affected by ultra-rare diseases. At Decisive Consulting, we recognise the critical importance of equitable access to innovative treatments in these uniquely challenging healthcare landscapes.

In our latest Decisive Dialogue, we explore the role of structured expert elicitation in highly specialised technology evaluations to fill data gaps and enhance evidence packages for the assessment of ultra-rare medicines.

Market access for gene therapies in rare diseases demands a comprehensive understanding of the intricate challenges and opportunities within healthcare ecosystems globally.

The Chinese healthcare industry has witnessed significant transformations, particularly in market access and negotiations for the National Reimbursement Drug List (NRDL). These changes, observed from both consulting and industry practice perspectives, reflect a strategic shift in China's approach and attitude towards healthcare and access to innovative medicines.